Literature DB >> 32596791

Cardiac amyloidosis detection by early bisphosphonate (99mTc-HMDP) scintigraphy.

M F Santarelli1,2, D Genovesi3, V Positano3, R Di Sarlo4, M Scipioni5,6, A Giorgetti3, L Landini3,4, P Marzullo3.   

Abstract

OBJECTIVE: To determine one or more indexes able to detect the presence of cardiac amyloidosis (CA) from planar scintigraphy images after injection of 99mTc-HMDP tracer and to identify the earliest acquisition time able to ensure an accurate diagnosis of amyloid transthyretin CA. METHODS AND
RESULTS: A total of 38 patients were included: 18 subjects with a final diagnosis of ATTR-CA and 20 controls. Dynamic planar images of the anterior thorax were acquired, starting at intravenous injection of ≈ 700 MBq of 99mTc-HMDP. From time/activity curves (TAC) of regions of interest such as heart, vascular region, right ribcage, and soft tissues, several indices were considered. From the analysis, it resulted that both TACHeart/Bone(t) and RIheart-bone(t), for t > 6 minutes, well distinguish ATTR-CA patients from controls subjects. This is confirmed by the area under curves (AUC) analysis giving AUC values =.9 at t ≅ 6 minutes and AUC ≅ 1 for t > 10 minutes.
CONCLUSIONS: The method proposed allows determining the presence of ATTR-CA, in an inexpensive manner both in terms of examination costs and time spent.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Amyloid transthyretin (ATTR); Cardiac amyloidosis; Dynamic time-activity curves; Early 99mTc-HMDP scintigraphy; Retention index

Mesh:

Substances:

Year:  2020        PMID: 32596791     DOI: 10.1007/s12350-020-02239-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  4 in total

Review 1.  PET/CT for Diagnosis and Management of Large-Vessel Vasculitis.

Authors:  Matthieu Pelletier-Galarneau; Terrence D Ruddy
Journal:  Curr Cardiol Rep       Date:  2019-03-18       Impact factor: 2.931

2.  Early Phase 99Tc-HMDP Scintigraphy for the Diagnosis and Typing of Cardiac Amyloidosis.

Authors:  Arnault Galat; Axel Van der Gucht; Aziz Guellich; Diane Bodez; Anne-Ségolène Cottereau; Soulef Guendouz; Luc Hittinger; Jean-Luc Dubois-Randé; Violaine Plante-Bordeneuve; Emmanuel Itti; Michel Meignan; Thibaud Damy; Jean Rosso
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-13

3.  Noninvasive risk stratification of patients with transthyretin amyloidosis.

Authors:  Arnt V Kristen; Katrin Scherer; Sebastian Buss; Fabian aus dem Siepen; Sabine Haufe; Ralf Bauer; Katrin Hinderhofer; Evangelos Giannitsis; Stefan Hardt; Uwe Haberkorn; Hugo A Katus; Henning Steen
Journal:  JACC Cardiovasc Imaging       Date:  2014-04-09

4.  Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy.

Authors:  Vasileios Papantoniou; Pipitsa Valsamaki; Stathis Kastritis; Spyridon Tsiouris; Zisis Delichas; Yiannis Papantoniou; Maria Tsiouma; Theodoros Athanasoulis; Andreas Fotopoulos; Meletios Athanasios Dimopoulos
Journal:  Hell J Nucl Med       Date:  2015 Sep-Dec       Impact factor: 1.102

  4 in total
  2 in total

1.  Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging.

Authors:  Fabio Minutoli; Massimo Russo; Gianluca Di Bella; Riccardo Laudicella; Alessandro Spataro; Antonio Vento; Alessio Comis; Luca Gentile; Anna Mazzeo; Giuseppe Vita; Sergio Baldari
Journal:  Eur Radiol       Date:  2022-01-15       Impact factor: 5.315

2.  Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images.

Authors:  M F Santarelli; D Genovesi; M Scipioni; V Positano; B Favilli; A Giorgetti; G Vergaro; L Landini; M Emdin; P Marzullo
Journal:  J Nucl Cardiol       Date:  2021-04-16       Impact factor: 3.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.